Monday, 13 April 2015

Horizon gets FDA Fast Track Designation for ACTIMMUNE to treat Friedreich's Ataxia

Horizon Pharma plc has announced that ACTIMMUNE® has been granted Fast Track designation from the U.S. Food and Drug Administration (FDA), to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.

via Latest News

No comments:

Post a Comment